Trials / Unknown
UnknownNCT02399566
Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma
Comparative Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- Hunan Province Tumor Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare effects of erlotinib and pemetrexed as maintenance therapy for lung adenocarcinoma. Primary Outcome is the progression free survival (PFS). Based on prediction of different potential benefit groups, this study may help the oncologist to optimize and improve the maintenance therapy plan for lung adenocarcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Erlotinib, Pemetrexed | followed classical chemotherapy for 4 cycles, use Erlotinib orally for the maintenance therapy. |
Timeline
- Start date
- 2015-05-01
- Primary completion
- 2018-01-01
- Completion
- 2019-01-01
- First posted
- 2015-03-26
- Last updated
- 2015-03-26
Source: ClinicalTrials.gov record NCT02399566. Inclusion in this directory is not an endorsement.